A controversial proposed Medicare payment model aimed at incentivizing physicians to choose lower-cost drugs via new reimbursement formulas could still be adjusted, an official with the Centers for Medicare & Medicaid Services (CMS) announced during a Senate Committee on Finance hearing on June 28.
Describing the intent of the new program, CMS Deputy Administrator Patrick Conway, MD, told the committee that it would “test whether alternative drug payment designs will lead to a